T-cell/histiocyte-rich B-cell lymphoma: Biology, diagnosis, and management

Oncologist

Volumn 11, Issue 4, 2006, Pages 384-392

  Abramson, Jeremy S ^a,b  

^a HARVARD MEDICAL SCHOOL   (United States)

^b DANA FARBER CANCER INSTITUTE   (United States)

Author keywords

DLBCL; Hodgkin's disease; Lymphoma; Nodular lymphocyte predominant Hodgkin's lymphoma; Tumor infiltrating lymphocytes

Indexed keywords

CYCLOPHOSPHAMIDE; DOXORUBICIN; PREDNISONE; VINCRISTINE;

AGE DISTRIBUTION; B CELL LYMPHOMA; BIOLOGY; CANCER DIAGNOSIS; CLINICAL FEATURE; DIAGNOSTIC ACCURACY; GENE EXPRESSION; HUMAN; IMMUNE RESPONSE; IMMUNOHISTOCHEMISTRY; INFLAMMATION; LARGE CELL LYMPHOMA; MICROENVIRONMENT; PATHOLOGY; PREVALENCE; PRIORITY JOURNAL; PROGNOSIS; REVIEW; SEX DIFFERENCE; T CELL HISTIOCYTE RICH B CELL LYMPHOMA; TUMOR CELL; TUMOR IMMUNITY;

CLINICAL TRIALS; HUMANS; LYMPHOMA, B-CELL; LYMPHOMA, LARGE-CELL, DIFFUSE; LYMPHOMA, T-CELL;

EID: 33645754476     PISSN: 10837159     EISSN: 1549490X     Source Type: Journal    
DOI: 10.1634/theoncologist.11-4-384     Document Type: Review

References (54)

1. Armitage JO, Weisenburger DD. New approach to classifying non-Hodgkin's lymphomas: clinical features of the major histologic subtypes. Non-Hodgkin's Lymphoma Classification Project. J Clin Oncol 1998;162780-2795.
2. Gatter KC, Warnke RA. Diffuse large B-cell lymphoma. In: Jaffe ES, Harris NL, Stein H et al., eds. Tumours of Haematopoietic and Lymphoid Tissues. Lyon: IARC Press, 2001:171-174.
3. Pfreundschuh M, Trumper L, Kloess M et al. Two-weekly or 3-weekly CHOP chemotherapy with or without etoposide for the treatment of elderly patients with aggressive lymphomas: results of the NHL-B2 trial of the DSHNHL. Blood 2004;104:634-641.
4. Pfreundschuh M, Trumper L, Kloess M et al. Two-weekly or 3-weekly CHOP chemotherapy with or without etoposide for the treatment of young patients with good-prognosis (normal LDH) aggressive lymphomas: results of the NHL-B1 trial of the DSHNHL. Blood 2004;104:626-633.
5. Bouabdallah R, Mounier N, Guettier C et al. T-cell/histiocyte-rich large B-cell lymphomas and classical diffuse large B-cell lymphomas have similar outcome after chemotherapy: a matched-control analysis. J Clin Oncol 2003;21:1271-1277.
6. Sehn LH, Donaldson J, Chhanabhai M et al. Introduction of combined CHOP plus rituximab therapy dramatically improved outcome of diffuse large B-cell lymphoma in British Columbia. J Clin Oncol 2005;23:5027-5033.
7. Ramsay AD, Smith WJ, Isaacson PG. T-cell-rich B-cell lymphoma. Am J Surg Pathol 1988;12:433-443.
8. Delabie J, Vandenberghe E, Kennes C et al. Histiocyte-rich B-cell lymphoma. A distinct clinicopathologic entity possibly related to lymphocyte predominant Hodgkin's disease, paragranuloma subtype. Am J Surg Pathol 1992;16:37-48.
9. Boudova L, Torlakovic E, Delabie J et al. Nodular lymphocyte-predominant Hodgkin lymphoma with nodules resembling T-cell/histiocyte-rich B-cell lymphoma: differential diagnosis between nodular lymphocyte-predominant Hodgkin lymphoma and T-cell/histiocyte-rich B-cell lymphoma. Blood 2003;102:3753-3758.
10. Rudiger T, Gascoyne RD, Jaffe ES et al. Workshop on the relationship between nodular lymphocyte predominant Hodgkin's lymphoma and T cell/histiocyte-rich B cell lymphoma. Ann Oncol 2002;13(suppl 1):44-51.
11. Shimodaira S, Hidaka E, Katsuyama T. Clonal identity of nodular lymphocyte-predominant Hodgkin's disease and T-cell-rich B-cell lymphoma. N Engl J Med 2000;343:1124-1125.
12. Aki H, Tuzuner N, Ongoren S et al. T-cell-rich B-cell lymphoma: a clinicopathologic study of 21 cases and comparison with 43 cases of diffuse large B-cell lymphoma. Leuk Res 2004;28:229-236.
13. Wang J, Sun NC, Chen YY et al. T-cell/histiocyte-rich large B-cell lymphoma displays a heterogeneity similar to diffuse large B-cell lymphoma: a clinicopathologic, immunohistochemical, and molecular study of 30 cases. Appl Immunohistochem Mol Morphol 2005;13:109-115.
14. Achten R, Verhoef G, Vanuytsel L et al. T-cell/histiocyte-rich large B-cell lymphoma: a distinct clinicopathologic entity. J Clin Oncol 2002;20:1269-1277.
15. Fraga M, Sanchez-Verde L, Forteza J et al. T-cell/histiocyte-rich large Bcell lymphoma is a disseminated aggressive neoplasm: differential diagnosis from Hodgkin's lymphoma. Histopathology 2002;41:216-229.
16. Lim MS, Beaty M, Sorbara L et al. T-cell/histiocyte-rich large B-cell lymphoma: a heterogeneous entity with derivation from germinal center B cells. Am J Surg Pathol 2002;26:1458-1466.
17. Greer JP, Macon WR, Lamar RE et al. T-cell-rich B-cell lymphomas: diagnosis and response to therapy of 44 patients. J Clin Oncol 1995;13:1742-1750.
18. McBride JA, Rodriguez J, Luthra R et al. T-cell-rich B large-cell lymphoma simulating lymphocyte-rich Hodgkin's disease. Am J Surg Pathol 1996;20:193-201.
19. Stein H, Delsol G, Pileri A et al. Classical Hodgkin lymphoma. In: Jaffe ES, Harris NL, Stein H et al., eds. Tumours of Haematopoietic and Lymphoid Tissues. Lyon: IARC Press, 2001:244-253.
20. Stein H, Delsol G, Pileri A et al. Nodular lymphocyte predominant Hodgkin lymphoma. In: Jaffe ES, Harris NL, Stein H et al., eds. Tumours of Haematopoietic and Lymphoid Tissues. Lyon: IARC Press, 2001:240-243.
21. Chittal SM, Brousset P, Voigt JJ et al. Large B-cell lymphoma rich in T-cells and simulating Hodgkin's disease. Histopathology 1991;19:211-220.
22. Rodriguez J, Pugh WC, Cabanillas F. T-cell-rich B-cell lymphoma. Blood 1993;82:1586-1589.
23. Krishnan J, Wallberg K, Frizzera G. T-cell-rich large B-cell lymphoma. A study of 30 cases, supporting its histologic heterogeneity and lack of clinical distinctiveness. Am J Surg Pathol 1994;18:455-465.
24. Feugier P, Van Hoof A, Sebban C et al. Long-term results of the R-CHOP study in the treatment of elderly patients with diffuse large B-cell lymphoma: a study by the Groupe d'Etude des Lymphomes de l'Adulte. J Clin Oncol 2005;23:4117-4126.
25. Pfreundschuh M, Trumper L, Gill D et al. First analysis of the completed Mabthera International (MInT) trial in young patients with low-risk diffuse large B-cell lymphoma (DLBCL): addition of rituximab to a CHOP-like regimen significantly improves outcome of all patients with the identification of a very favorable subgroup with IPI=O and no bulky disease. Blood 2004;104:48a.
26. Abramson JS, Shipp MA. Advances in the biology and therapy of diffuse large B-cell lymphoma: moving toward a molecularly targeted approach. Blood 2005;106:1164-1174.
27. Coiffier B. State-of-the-art therapeutics: diffuse large B-cell lymphoma. J Clin Oncol 2005;23:6387-6393.
28. Macon WR, Williams ME, Greer JP et al. T-cell-rich B-cell lymphomas. A clinicopathologic study of 19 cases. Am J Surg Pathol 1992;16:351-363.
29. Achten R, Verhoef G, Vanuytsel L et al. Histiocyte-rich, T-cell-rich B-cell lymphoma: a distinct diffuse large B-cell lymphoma subtype showing characteristic morphologic and immunophenotypic features. Histopathology 2002;40:31-45.
30. Gascoyne RD, Adomat SA, Krajewski S et al. Prognostic significance of Bcl-2 protein expression and bcl-2 gene rearrangement in diffuse aggressive non-Hodgkin's lymphoma. Blood 1997;90:244-251.
31. Kramer MH, Hermans J, Wijburg E et al. Clinical relevance of BCL2, BCL6, and MYC rearrangements in diffuse large B-cell lymphoma. Blood 1998;92 3152-3162.
32. Pileri SA, Dirnhofer S, Went P et al. Diffuse large B-cell lymphoma: one or more entities? Present controversies and possible tools for its subclassification. Histopathology 2002;41:482-509.
33. Chittal SM, Alard C, Rossi JF et al. Further phenotypic evidence that nodular, lymphocyte-predominant Hodgkin's disease is a large B-cell lymphoma in evolution. Am J Surg Pathol 1990;14:1024-1035.
34. Feugier P, Labouyrie E, Djeridane M et al. Comparison of initial characteristics and long-term outcome of patients with lymphocyte-predominant Hodgkin lymphoma and classical Hodgkin lymphoma at clinical stages IA and IIA prospectively treated by brief anthracycline-based chemotherapies plus extended high-dose irradiation. Blood 2004;104:2675-2681.
35. Torlakovic E, Tierens A, Dang HD et al. The transcription factor PU.1, necessary for B-cell development is expressed in lymphocyte predominance, but not classical Hodgkin's disease. Am J Pathol 2001;159:1807-1814.
36. Braeuninger A, Kuppers R, Strickler JG et al. Hodgkin and Reed-Sternberg cells in lymphocyte predominant Hodgkin disease represent clonal populations of germinal center-derived tumor B cells. Proc Natl Acad Sci U S A 1997;94:9337-9342.
37. Brauninger A, Kuppers R, Spieker T et al. Molecular analysis of single B cells from T-cell-rich B-cell lymphoma shows the derivation of the tumor cells from mutating germinal center B cells and exemplifies means by which immunoglobulin genes are modified in germinal center B cells. Blood 1999;93:2679-2687.
38. Miettinen M, Franssila KO, Saxen E. Hodgkin's disease, lymphocytic predominance nodular. Increased risk for subsequent non-Hodgkin's lymphomas. Cancer 1983;51:2293-2300.
39. Brauninger A, Hansmann ML, Strickler JG et al. Identification of common germinal-center B-cell precursors in two patients with both Hodgkin's disease and non-Hodgkin's lymphoma. N Engl J Med 1999;340:1239-1247.
40. Monti S, Savage KJ, Kutok JL et al. Molecular profiling of diffuse large B-cell lymphoma identifies robust subtypes including one characterized by host inflammatory response. Blood 2005;105:1851-1861.
41. Pages F, Berger A, Camus M et al. Effector memory T cells, early metastasis, and survival in colorectal cancer. N Engl J Med 2005;353:2654-2666.
42. Clark WH Jr, Elder DE, Guerry D 4th et al. Model predicting survival in stage I melanoma based on tumor progression. J Natl Cancer Inst 1989;81:1893-1904.
43. Zhang L, Conejo-Garcia JR, Katsaros D et al. Intratumoral T cells, recurrence, and survival in epithelial ovarian cancer. N Engl J Med 2003;348:203-213.
44. Strickler JG, Copenhaver CM, Rojas VA et al. Comparison of "host cell infiltrates" in patients with follicular lymphoma with and without spontaneous regression. Am J Clin Pathol 1988;90:257-261.
45. Dave SS, Wright G, Tan B et al. Prediction of survival in follicular lymphoma based on molecular features of tumor-infiltrating immune cells. N Engl J Med 2004;351:2159-2169.
46. Hsu FJ, Caspar CB, Czerwinski D et al. Tumor-specific idiotype vaccines in the treatment of patients with B-cell lymphoma - long-term results of a clinical trial. Blood 1997;89:3129-3135.
47. Garcia CF, Lowder J, Meeker TC et al. Differences in "host infiltrates" among lymphoma patients treated with anti-idiotype antibodies: correlation with treatment response. J Immunol 1985;135:4252-4260.
48. Re D, Kuppers R, Diehl V. Molecular pathogenesis of Hodgkin's lymphoma. J Clin Oncol 2005;23:6379-6386.
49. + T-cell immune response to large B-cell non-Hodgkin's lymphoma predicts patient outcome. J Clin Oncol 2001;19:720-726.
50. Lippman SM, Spier CM, Miller TP et al. Tumor-infiltrating T-lymphocytes in B-cell diffuse large cell lymphoma related to disease course. Mod Pathol 1990;3:361-367.
51. Parmiani G. Tumor-infiltrating T cells - friend or foe of neoplastic cells? N Engl J Med 2005;353:2640-2641.
52. Curiel TJ, Coukos G, Zou L et al. Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival. Nat Med 2004;10:942-949.
53. + regulatory T cells in the peripheral circulation of patients with head and neck cancer. Br J Cancer 2005;92:913-920.
54. Marshall NA, Christie LE, Munro LR et al. Immunosuppressive regulatory T cells are abundant in the reactive lymphocytes of Hodgkin lymphoma. Blood 2004;103:1755-1762.